In patients with heart failure and diabetes, sotagliflozin can lower glucose quite well, even when patients are facing suboptimal glomerular filtration rates, noted Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital and Harvard Medical School.
In a paper being presented during ESC Congress 2021, authors from the University of Copenhagen use a registry to mimic 2 well-known trials, finding explanations for some, but not all, of the gap in risk reduction between them.
Both REDUCE-IT and STRENGTH recruited people with very high triglycerides and tested different formulations of omega-3 fatty acids, but the results were different. About 12% of the difference can be explained, noted Børge G. Nordestgaard, MD, DMSc, Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, but 13% cannot be, given that REDUCE-IT had a 25% reduced risk of atherosclerotic cardiovascular disease.
There was a reduction in both the need for dialysis and progression to end-stage renal disease; finerenone was really well tolerated, stated Bertram Pitt, MD, professor of medicine emeritus, University of Michigan School of Medicine.
With finerenone being a targeted therapy, data show there may be an additive cardiorenal benefit when it is coadministered with a sodium glucose co-transporter 2 inhibitor, noted Dipti Itchhaporia, MD, FACC, FAHA, FESC, president of the American College of Cardiology.
Whatever your theory of heart failure with preserved ejection fraction, sodium glucose co-transporter 2 (SGLT2) inhibitors seem to be attacking every one, noted Javed Butler, MD, MPH, MBA, University of Mississippi.
A new study unveiled on day 2 of ESC Congress 2021 showed finerenone, a nonsteroidal mineralocorticoid receptor antagonist, offers benefits to patients with mild to moderate CKD and type 2 diabetes.
Findings from 5 studies presented on day 1 of ESC Congress 2021 indicate that there is still much to be learned on the complex interaction among COVID-19 infection, cardiovascular care, and heart failure.
Sodium glucose co-transporter 2 (SGLT2) inhibitor use in patients with heart failure with preserved ejection fraction (HFpEF) has generated great enthusiasm, noted Rudolf de Boer, MD, PhD, clinical cardiologist and professor of translational cardiology, University Medical Center Groningen, the Netherlands.
EMPEROR-Preserved represents the first trial to show unequivocal benefits of any drug on major heart failure outcomes in patients with heart failure and preserved ejection fraction, the lead investigator said.
The composite end point of cardiovascular death and heart failure hospitalization was reduced by 21%, which is highly statistically significant and clinically meaningful, noted Stefan Anker, MD, PhD, FESC, principal investigator of EMPEROR-Preserved.
The 5-year update could help solidify the role of sodium glucose co-transporter 2 (SGLT2) inhibitors in treating heart failure, years after the first evidence of their effectiveness emerged.
There are incredible data for sodium-glucose co-transporter 2 (SGLT2) inhibitors, and this is a great class of medicines that is vastly underutilized, stated Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School.
The lack of approved treatments for heart failure with preserved ejection fraction has represented a significant unmet need for a condition that affects 50% of patients with heart failure, including large subgroups, such as older women.
There will be new ESC heart failure guidelines and presentation of data from EMPEROR-Preserved and EMPEROR-Pooled, noted Rudolf de Boer, MD, PhD, of University Medical Center Groningen, the Netherlands.
Christopher Arendt, PhD, head, Oncology Therapeutic Area Unit, Takeda, speaks on the efficacy data of mobocertinib in patients with EGFR exon 20 mutations within metastatic non–small cell lung cancer (NSCLC) and its potential significance for these patient populations.
Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, outlines the benefits of sotagliflozin for individuals with type 2 diabetes and chronic kidney disease or heart failure.
The study was launched the same month as the first US approval of a sodium-glucose co-transporter 2 inhibitor, and the failure to include a drug from this class was viewed by a commentator as a weakness of GRADE.
Sanofi gave up rights to develop the glucagon-like peptide 1 receptor agonist last year after a change in strategy.
Camillo Ricordi, MD, FNAI, describes the process of islet transplantation and how it can benefit individuals with type 1 diabetes.
Catlin Dennis, MPH, describes her research on the impacts of COVID-19 on Oregon’s most medically and socially vulnerable youth with diabetes.
Leslie Eiland, MD, discusses the benefits of remote monitoring among patients with type 1 diabetes (T1D) living in rural America.
Bobeck Modjtahedi, MD, describes how Kaiser Permanente leveraged its telehealth resources to provide care to those with diabetic retinopathy (DR) throughout the COVID-19 pandemic.
Michelle Litchman, PHD, FNP-BC, FAANP, FADCES, an assistant professor at the College of Nursing at the University of Utah, highlights her research on the benefits of concurrent continuous glucose monitoring and online peer support groups for Spanish-speaking patients with diabetes.
How therapeutic advances can address all 3 conditions was the topic of a symposium Friday during the 81st Scientific Sessions of the American Diabetes Association (ADA), “The Intersection of Diabetes, Heart Failure and Kidney Disease: Challenges and New Insights.”
Aleksandar Kostic, PhD, an assistant professor of microbiology at Harvard Medical School, describes the research linking gut microbiota and incidence of type 1 diabetes.
Ezio Bonifacio, PhD, discusses the optimal time to begin monitoring for type 1 diabetes (T1D) in children genetically at risk for the disease.
Ann Goebel-Fabbri, PhD, a clinical psychologist in Boston, Massachusettes, outlines trends in eating disorders among patients with type 1 diabetes.
Mary Pat Gallagher, MD, of NYU Langone Health, explains her research documenting new onset diabetes and diabetic ketoacidosis (DKA) throughout the COVID-19 pandemic.
David McIntyre, MD, FRACP, gives an overview of his talk "Diagnosis and Management of Diabetes in Pregnancy During the COVID-19 Pandemic," to be presented at the American Diabetes Association's (ADA) 81st Scientific Sessions.
